MLICM
AGRX

Metropolitan Life Insurance Company (MetLife)’s Agile Therapeutics AGRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12
Closed -$70.3K – 2584
2020
Q3 		$70.3K Hold
12
– – ﹤0.01% 2403
2020
Q2 		$68.4K Buy
+12
New +$62.4K ﹤0.01% 2452

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AGRX Position: Q4 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Agile Therapeutics (AGRX) in Q4 2020, closing a stake of 12 shares — an estimated $70.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AGRX in Q2 2020 and held it in 2 quarters. The position peaked at $70.3K in Q3 2020. 76 funds tracked by Wall St. Rank hold AGRX as of Q4 2020.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Agile Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 12 Agile Therapeutics shares in Q4 2020, an estimated $70.3K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Agile Therapeutics in Q2 2020 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Agile Therapeutics position peaked at $70.3K in Q3 2020.
  • 76 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2020, filed 16 Feb 2021.